Diana M. Abraham

Diana M. Abraham

Auto-generated profile, based on publicly available information

Diana M. Abraham

Translational Stem Cell Biology Branch, National Heart, Lung, and Blood Institute/National Institutes of Health, Bethesda, MD

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Cell Stem Cell
Verified
Journal Article
Closed access
NTNaren P. Tallapragada
Naren P. Tallapragada
HCHailey M. Cambra
Hailey M. Cambra
TWTomas Wald
Tomas Wald
SJSamantha Keough Jalbert
Samantha Keough Jalbert
DADiana M. Abraham
Diana M. Abraham
AKAllon M. Klein
Allon M. Klein

27 November 2021 in Journal of Biomedical Materials Research Part B: Applied Biomaterials
Verified
Journal Article
Closed access
PDF file
DADiana M. Abraham
Diana M. Abraham
CHCalvin Herman
Calvin Herman
Lukasz WitekLukasz Witek
Lukasz Witek
BCBruce Cronstein
Bruce Cronstein
RFRoberto L Flores
Roberto L Flores
PCPaulo G. Coelho
Paulo G. Coelho

6 December 2022 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
DADiana M. Abraham
Diana M. Abraham
RLRichard J. Lozano
Richard J. Lozano
XGXavi Guitart
Xavi Guitart
JLJialiu A. Liang
Jialiu A. Liang
RMRyland D. Mortlock
Ryland D. Mortlock
CDCynthia E. Dunbar
Cynthia E. Dunbar
The clonal dynamics following hematopoietic stem progenitor cell (HSPC) transplantation with busulfan conditioning are of great interest to the development of HSPC gene therapies. Compared with total body irradiation (TBI), busulfan is less toxic and more clinically relevant. We used a genetic barcoded HSPC autologous transplantation model to investigate the impact of busulfan conditioning on hematopoietic reconstitution in rhesus macaques. Two animals received lower busulfan dose and demonstrated lower vector marking levels compared with the third animal given a higher busulfan dose, despite similar busulfan pharmacokinetic analysis. We observed uni-lineage clonal engraftment at 1 month post-transplant, replaced by multilineage clones by 2 to 3 months in all animals. The initial multilineage clones in the first two animals were replaced by a second multilineage wave at 9 months; this clonal pattern disappeared at 13 months in the first animal, though was maintained in the second animal. The third animal maintained stable multilineage clones from 3 months to the most recent time point. In addition, busulfan animals exhibit more rapid HSPC clonal mixing across bone marrow sites and less CD16+ NK-biased clonal expansion compared with TBI animals. Therefore, busulfan conditioning regimens can variably impact the marrow niche, resulting in differences in clonal patterns with implications for HSPC gene therapies.

6 April 2026 in Blood Advances
Verified
Journal Article
Open access
THTaha Bartu Hayal
Taha Bartu Hayal
DADiana M. Abraham
Diana M. Abraham
SDSelami Demirci
Selami Demirci
XFXing Fan
Xing Fan
YZYifan Zhou
Yifan Zhou
CDCynthia E. Dunbar
Cynthia E. Dunbar
Compared with total body irradiation (TBI) or chemotherapy, antibody-drug conjugates (ADCs) offer a more targeted and potentially less toxic method for transplantation conditioning. CD45-ADC targets a pan-leukocyte antigen expressed on hematopoietic stem and progenitor cells (HSPCs) and immune cells, offering a promising strategy for gene therapy or allogeneic transplantation. We evaluated reconstitution, clonal dynamics, immune tolerance, and toxicity after conditioning with a DGN549-C–conjugated CD45-ADC followed by autologous transplantation in rhesus macaques. Two doses (0.2 and 0.3 mg/kg) were tested, with HSPC infusion 10 days after conditioning. All animals received barcoded, copepod green fluorescent protein (CopGFP)-expressing lentivirally transduced HSPCs. Both doses resulted in profound depletion of HSPCs and expected cytopenias, with incomplete lymphocyte depletion. With 0.2 mg/kg CD45-ADC conditioning, 2 animals showed robust multilineage engraftment with gene-modified cells and high clonal diversity, comparable with TBI. However, CopGFP+ cell levels and clonal diversity declined at 4 to 8 months, accompanied by development of anti-CopGFP antibodies, suggesting immune rejection. Incomplete T-cell depletion may have contributed. Notably, this rejection was slower and less complete than that after busulfan conditioning, suggesting partial immune tolerance. Dexamethasone treatment in 1 animal reversed rejection and stabilized CopGFP+ levels for >2 years. At 0.3 mg/kg CD45-ADC, 2 animals developed severe respiratory distress 4 to 6 days after transplantation, requiring humane euthanasia, accompanied by elevated inflammatory cytokines. This severe syndrome was not seen in 9 additional animals conditioned with CD45-ADC. These findings highlight the importance of preclinical evaluation of experimental therapeutics. Combining lower-dose CD45-ADC with immune suppression may enable durable engraftment in settings of alloantigen or neoantigen expression.